An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.
How ICER Gets It Wrong
An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.